Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 152

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 152
---
 our drug delivery, preclinical development activities, laboratory testing and clinical trials
    for our drug candidate;

    ●
    the
    number and scope of clinical programs we decide to pursue;

    ●
    the
    scope and costs of manufacturing development and commercial manufacturing activities;

    ●
    the
    extent to which we acquire or in-license other drug candidate and technologies;

    ●
    the
    cost, timing and outcome of regulatory review of our drug candidate;

    ●
    the
    cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval;

    ●
    the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights
    and defending intellectual property-related claims;

    ●
    our
    ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our drug candidate;

    ●
    The
    amount of profit, if any, generated from the sales of the Nugevia product line;

    ●
    the
    costs associated with being a public company; and

    ●
    the
    cost associated with commercializing our drug candidate, if it receives marketing approval.

See
“Risk Factors” included herein and in our Annual Report on Form 10-K for additional discussion of risks associated
with our capital requirements.

28

Cash
Flows for the Nine months ended September 30, 2025 and 2024

The
following table shows a summary of our cash flows for the nine months ended September 30, 2025 and 2024.

    For
    the Nine months ended 
September 30, 

    2025  
    2024 
  
    Net
    cash flows from operating activities 
    $(3,045,713) 
    $(215,225)
  
    Net
    cash flows from investing activities 
     -  
     - 
  
    Net
    cash flows from financing activities 
    $-  
    $187,000 
  
    Net
    increase (decrease) in cash 
    $(3,045,713) 
    $(28,225)

Net
Cash Flows From Operating Activities:

Net
cash used in operating activities during the nine months ended September 30, 2025